Preferences help
enabled [disable] Abstract
Number of results
2018 | 108 | 133-143
Article title

Newest therapeutic options for adrenoleukodystrophy

Title variants
Languages of publication
X-linked adrenoleukodystrophy is a genetic disease correlated with mutation of ATP-binding cassette, which results in errors of peroxisomal beta oxidation and accumulation of impaired very long chain fatty acids. This leads to degeneration of adrenal glands, spinal cord and myelin sheaths. Despite nearly 100 years of ALD history, the treatment is limited to few therapeutic options, mainly Lorenzo’s Oil and Hematopoetic stem cell transplant. Available therapy can only slow the progression of the disease in early stages. The aim of our study was to present the newest therapeutic options in X-ALD. Substantial articles on new treatment of X-ALD from period 2007-2018 in the Asian, European and American regions have been analyzed. Among 219 articles in PubMed Medline database related to therapy and treatment of X-ALD, 13 articles were selected for analysis, reviewed and divided into two main groups: cause-related treatment (11 articles) and symptoms-related treatment (2 articles). Within cause-related treatment, the usage of known medications such as eg. pioglitazone, natural phenols - resveratrol, gene therapy with adenoassociated virus serotype 9 or combined therapies (Hematopoetic Stem Cell Gene Therapy) have been reviewed. Symptoms related treatment attempted to reduce spasticity and secondary dystonia in X-ALD patients. Reviewed research presents progress in development of treatment options for X-ALD, however still in primary in vitro and animal tested stages. Secondary neurological symptoms medication is awaiting for better solutions for ALD patients, in order to improve their Quality of Life and allow symptomless course for a longer time.
Physical description
  • I Faculty of Medicine, Medical University of Lublin, Al. Raclawickie 1, 20-059 Lublin, Poland
  • Pediatric Neurology Department, III Chair of Pediatrics, Medical University of Lublin, 6 Prof. A. Gebali 6 Str., 20-093 Lublin, Poland
  • Department of Pediatric Endocrinology and Diabetology with Endocrine - Metabolic Laboratory, III Chair of Pediatrics, Medical University of Lublin, 6 Prof. A. Gebali 6 Str., 20-093 Lublin, Poland
  • [1] Lerner BH. Complicated lessons: Lorenzo Odone and medical miracles. Lancet (2009) Mar 14; 373 (9667): 888-9.
  • [2] Odone A, Odone M. More on Lorenzo's oil. N Engl J Med. (1994) Jun 30; 330 (26): 1904-5.
  • [3] Moser HW. Komrower Lecture. Adrenoleukodystrophy: natural history, treatment and outcome. J Inherit Metab Dis. (1995) 18(4): 435-47.
  • [4] Engelen M, Kamp S, de Visser M, van Geel BM, Wanders RJA et al. X-linked adrenoleukodystrophy (X-ALD): clinical presentation and guidelines for diagnosis, follow-up and management. Orphanet Journal of Rare Diseases (2012) 7: 5
  • [5] Morato L, Galino J, Ruiz M, Calingasan NY, Starkov AA, et al. Pioglitazone halts axonal degeneration in a mouse model of X-linked adrenoleukodystrophy Brain (2013) 136; 2432–2443
  • [6] van Kamebeek C, Horvath G, Murphy T, Purtzki J, Bowden K et al. Deep Brain Stimulation and Dantrolene for Secondary Dystonia in X-Linked Adrenoleukodystrophy. JIMD Reports DOI 10.1007/8904_2014_305
  • [7] Fourcade S, Lopez-Erauskin J, Galino J, Duval C, Naudi A et al. Early oxidative damage underlying neurodegeneration in X-adrenoleukodystrophy. Hum Mol Genet (2008) 17: 1762–73.
  • [8] Moser HW, Raymond GV, Lu SE, Muenz LR, Moser AB et al. Follow-up of 89 asymptomatic patients with adrenoleukodystrophy treated with Lorenzo’s oil. Arch Neurol. (2005) 62(7): 1073–80.
  • [9] Miller WP, Rothman SM, Nascene D, Kivisto T, DeFor TE et al. Outcomes after allogeneic hematopoietic cell transplantation for childhood cerebral adrenoleukodystrophy: the largest single-institution cohort report. Blood. (2011) 118(7): 1971–8.
  • [10] Gong Y, Mu D, Prabhakar S, Moser A, Musolino P et al. Adenoassociated Virus Serotype 9-Mediated Gene Therapy for X-Linked Adrenoleukodystrophy. Mol Ther. (2015), 23(5): 824–834
  • [11] Morato L, Ruiz M, Boada J, Calingasan NY, Galino J et al. Activation of sirtuin 1 as therapy for the peroxisomal disease adrenoleukodystrophy. Cell Death Differ. (2015) 22, 1742–1753
  • [12] Jang J, Kim HS, Kang JW, Kang HC. The Genetically Modified Polysialylated Form of Neural Cell Adhesion Molecule-Positive Cells for Potential Treatment of X-Linked Adrenoleukodystrophy. Yonsei Med J (2013), 54(1): 246-252.
  • [13] Nagabhushan Kalburgi S, Khan NN, Gray SJ. Recent Gene Therapy Advancements for Neurological Diseases. Discov Med. (2013) 15(81): 111–119.
  • [14] Eichler F, Duncan C, Musolino PL, Orchard PJ, De Oliveira S, et al. Hematopoietic Stem-Cell Gene Therapy for Cerebral Adrenoleukodystrophy. N Engl J Med (2017) 377: 1630-1638
  • [15] Pujol A, Ferrer I, Camps C, Metzger E, Hindelang C et al. Functional overlap between ABCD1 (ALD) and ABCD2 (ALDR) transporters: a therapeutic target for X-adrenoleukodystrophy. Hum Mol Genet. (2004) 13: 2997–3006.
  • [16] Netik A, Forss-Petter S, Holzinger A, Molzer B, Unterrainer G, Berger J. Adrenoleukodystrophyrelated protein can compensate functionally for adrenoleukodystrophy protein deficiency (XALD): implications for therapy. Hum Mol Genet. (1999) 8: 907–913.
  • [17] Singh J, Khan M, Singh I. Caffeic Acid Phenethyl Ester Induces Adrenoleukodystrophy (Abcd2) Gene in Human X-ALD Fibroblasts and Inhibits the Proinflammatory Response in Abcd1/2 Silenced Mouse Primary Astrocytes. Biochim Biophys Acta (2013) 1831(4): 747–758. doi:10.1016/j.bbalip.2013.01.004
  • [18] Baarine M, Beeson C, Singh A, Singh I. ABCD1 deletion-induced mitochondrial dysfunction is corrected by SAHA: implication for adrenoleukodystrophy. J Neurochem. (2015) 133(3): 380–396. doi:10.1111/jnc.12992.
  • [19] Singh J, Khan M, Pujol A, Baarine M, Singh I. Histone Deacetylase Inhibitor Upregulates Peroxisomal Fatty Acid Oxidation and Inhibits Apoptotic Cell Death in Abcd1-Deficient Glial Cells. PLOS One (2013) 8(7): e70712
  • [20] Troffer-Charlier N, Doerflinger N, Metzger E, Fouquet F, Mandel JL, et al. Mirror expression of adrenoleukodystrophy and adrenoleukodystrophy related genes in mouse tissues and human cell lines. Eur J Cell Biol (1998) 75: 254–264. doi:10.1016/S0171-9335(98)80121-0
  • [21] Weber FD, Weinhofer I, Einwich A, Forss-Petter S, Muneer Z et al. Evaluation of Retinoids for Induction of the Redundant Gene ABCD2 as an Alternative Treatment Option in X-Linked Adrenoleukodystrophy. PLOS One (2014) 9(7): e103742.
  • [22] Hjartarson HT, Ehrstedt C, Tedroff K. Intrathecal baclofen treatment an option in X-linked Adrenoleukodystrophy. Eur J Paediatr Neurol. 2018 Jan; 22(1): 178-181
  • [23] Temel Y, Kessels A, Tan S, Topdag A, Boon P, Visser- Vandewalle V. Behavioural changes after bilateral subthalamic stimulation in advanced Parkinson disease: a systematic review. Parkinsonism Related Disorders (2006) 12: 265-272.
  • [24] Baldermann J.C., Schuller T, Huys D., Becker I., Timmermann L., Jessen F., Visser-Vandewalle V., Kuhn J. Deep Brain Stimulation for Tourette-Syndrome: A Systematic Review and Meta-Analysis. Brain Stimulation (2016) 9: 296–304
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.